Form 990 for tax year 2022

Totals

Total revenue

$37,806,927

Total expenses

$34,336,709

Contributions and grants received

$37,801,756

Grants paid

$3,161

Program service revenue

$0

Investment income

$5,171

Other revenue

$0

Total assets, end of year

$10,449,118

Total liabilities, end of year

$14,538,729

Net assets or fund balances, end of year

-$4,089,611

Program services expenses (Part IX)

$27,382,649

Management and general expenses

$6,954,060

Fundraising expenses

$0

Program service expenses (Part III)

$27,382,649

Program services were 79.7% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Mission and programs · 2022

• SEE SCHEDULE O DURING 2022, JCHR HAD 49 ACTIVE CLINICAL STUDIES. IN ADDITION TO INDUSTRY COLLABORATIONS, JCHR RECEIVED GRANTS FROM THE NATIONAL INSTITUTES OF HEALTH (8), HELMSLEY CHARITABLE TRUST (10), JDRF (5), FOUNDATION FIGHTING BLINDNESS (5), CYSTIC FIBROSIS FOUNDATION (2), AND FOOD AND DRUG ADMINISTRATION (1). JCHR ALSO SELF-FUNDED ONE STUDY AND NUMEROUS STATISTICAL ANALYSIS PROJECTS USING DATASETS FROM PREVIOUSLY COMPLETED STUDIES. SEVERAL STUDIES ARE FUNDED BY MULTIPLE SOURCES. FOR EXAMPLE, ONE CLINICAL TRIAL EVALUATING FENOFIBRATE FOR DIABETIC RETINOPATHY IS A LARGE COLLABORATION WITH FUNDS PROVIDED BY THE NATIONAL INSTITUTES OF HEALTH (NATIONAL EYE INSTITUTE AND NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASE), JDRF, HELMSLEY CHARITABLE TRUST, AND ROCHE. NINE NEW GRANTS, CONTRACTS, OR SUBAWARDS BEGAN DURING THE YEAR. AMONG 2,859 ENTITIES RECEIVING NIH FUNDING IN 2022, JCHR RANKS IN THE TOP 9%. OUT OF 65,306 NIH GRANTS PROVIDED IN 2022, JCHR HAD THE 173RD (TOP 0.3%) AND 581ST (TOP 0.9%) LARGEST GRANTS (SOURCE: BLUE RIDGE INSTITUTE FOR MEDICAL RESEARCH, 2022). JCHR PROJECTS HAD 62 MANUSCRIPTS ACCEPTED OR PUBLISHED AND 53 PRESENTATIONS MADE AT NATIONAL AND INTERNATIONAL MEETINGS IN 2022. RESULTS FROM THESE MANUSCRIPTS INCLUDE THE FOLLOWING FOUR THAT WERE PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: A RANDOMIZED TRIAL OF BIONIC PANCREAS TREATMENT IN TYPE 1 DIABETES DEMONSTRATED THAT AT 13 WEEKS, BIONIC PANCREAS USE WAS ASSOCIATED WITH A GREATER REDUCTION IN HBA1C THAN STANDARD CARE. UNLIKE CURRENTLY AVAILABLE SEMIAUTOMATED INSULIN-DELIVERY SYSTEMS, THE BIONIC PANCREAS DOES NOT REQUIRE CARBOHYDRATE COUNTING FOR ROUTINE OPERATION. A RANDOMIZED TRIAL IN VERY YOUNG CHILDREN WITH TYPE 1 DIABETES (AGES 1 TO 7) SHOWED IMPROVED GLYCEMIC CONTROL WITH THE USE OF A HYBRID CLOSED-LOOP SYSTEM (I.E., ARTIFICIAL PANCREAS) WITHOUT INCREASING TIME SPENT IN HYPOGLYCEMIC RANGE. A RANDOMIZED TRIAL IN YOUTHS (10 TO <17 YEARS) WITH NEW ONSET TYPE 1 DIABETES DEMONSTRATED THAT HYBRID CLOSED-LOOP THERAPY DID NOT PREVENT THE DECLINE OF RESIDUAL C-PEPTIDE SECRETION OVER 24 MONTHS COMPARED WITH STANDARD INSULIN TREATMENT. A RANDOMIZED TRIAL IN EYES WITH DIABETIC MACULAR EDEMA WITH MODERATE VISION LOSS FOUND NO SIGNIFICANT DIFFERENCE IN VISUAL ACUITY OVER TWO YEARS BETWEEN INJECTIONS OF AFLIBERCEPT MONOTHERAPY (~$1,830 PER INJECTION) AND INJECTIONS OF BEVACIZUMAB FIRST (~$70 PER INJECTION) WITH A SWITCH TO AFLIBERCEPT WHEN THERE WAS SUBOPTIMAL RESPONSE.IN ADDITION TO CONVENTIONAL CLINIC-BASED CLINICAL TRIALS, JCHR CONDUCTED SEVERAL "DIRECT TO-PATIENT" STUDIES IN WHICH JCHR STAFF HAD VIRTUAL CONTACT WITH STUDY PARTICIPANTS WHO PROVIDED DATA VIA THE INTERNET AND FROM DEVICES: (1) A STUDY TO COLLECT DEVICE DATA DURING EXERCISE IN ADULTS WITH TYPE 1 DIABETES; (2) A STUDY TO COLLECT DEVICE DATA DURING EXERCISE IN YOUTH WITH TYPE 1 DIABETES; (3) A STUDY TO PROVIDE VIRTUAL CLINIC SUPPORT FOR ADULTS WITH TYPE 1 OR TYPE 2 DIABETES THAT INCLUDED SUPPORT FOR THE USE OF DIABETES TECHNOLOGY AS WELL AS BEHAVIORAL HEALTH SUPPORT; AND (4) A STUDY TO COLLECT REAL-WORLD DATA FROM A DIABETES MANAGEMENT SYSTEM THAT DISPLAYS AND TRACKS HEALTHCARE PROVIDER-RECOMMENDED INSULIN DOSING INFORMATION.

  Expenses $27,382,649 · Grants $3,161

As filed on the 2022 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Related organizations on this return

Schedule R Part II: tax-exempt organizations related to the filer by control. It does not record shared board members or money.

• JAEB CENTER RESEARCH TRUST INC

  501(C)(3) · SUPPORT · FL

Provenance

Return type

form_990

Tax year

2022

Filed

9 May 2023

IRS schema version

2022v5.0

Source object

202331319349301213

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.